DiaGenic

NEW YORK (GenomeWeb News) – Norwegian biomarker diagnostics firm DiaGenic today announced the initiation of a cost reduction program, which includes the elimination of an undisclosed number of jobs.

Norwegian molecular diagnostic developer DiaGenic said this week that it has adopted Life Technologies' recently launched QuantStudio Dx platform to further enable development of its pipeline of multi-biomarker blood-based molecular assays for Alzheimer's disease.

DiaGenic has named Paul de Potocki as president and CEO, effective in September.

NEW YORK (GenomeWeb News) – DiaGenic today said that it has received a NOK 7.8 million ($1.3 million) grant from the Norwegian Research Council for an Alzheimer's disease diagnostics program.

DiaGenic said this week that CEO Erik Christensen has resigned.
Christensen will "continue to provide consultative support to the company on partner interactions, licensing and other business activities," DiaGenic said in a statement.

The story has been updated to clarify the nature of the test in the headline.
By a GenomeWeb staff reporter

After the split, the Norwegian firm had about 27 million shares of common stock outstanding.

The firm terminated its market-making contract with the investment firm, as trading of its stock has been "very high."

The firms will use DiaGenic's gene expression technology in a study to identify biomarkers related to patients who progress from mild cognitive impairment to Alzheimer's.

Pages

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.